391 related articles for article (PubMed ID: 18006079)
1. Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
Weide B; Garbe C; Rammensee HG; Pascolo S
Immunol Lett; 2008 Jan; 115(1):33-42. PubMed ID: 18006079
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccination against tumors.
Prud'homme GJ
J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731
[TBL] [Abstract][Full Text] [Related]
3. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
Pavlenko M; Leder C; Pisa P
Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
[TBL] [Abstract][Full Text] [Related]
4. RNA transfected dendritic cells as cancer vaccines.
Mitchell DA; Nair SK
Curr Opin Mol Ther; 2000 Apr; 2(2):176-81. PubMed ID: 11249639
[TBL] [Abstract][Full Text] [Related]
5. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
Anderson RJ; Schneider J
Vaccine; 2007 Sep; 25 Suppl 2():B24-34. PubMed ID: 17698262
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccination and gene therapy: optimization and delivery for cancer therapy.
Bodles-Brakhop AM; Draghia-Akli R
Expert Rev Vaccines; 2008 Sep; 7(7):1085-101. PubMed ID: 18767956
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
8. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.
Michiels A; Tuyaerts S; Bonehill A; Heirman C; Corthals J; Thielemans K
Methods Mol Biol; 2008; 423():155-63. PubMed ID: 18370196
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic cancer vaccines.
Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
[TBL] [Abstract][Full Text] [Related]
10. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.
Quaak SG; van den Berg JH; Toebes M; Schumacher TN; Haanen JB; Beijnen JH; Nuijen B
Eur J Pharm Biopharm; 2008 Oct; 70(2):429-38. PubMed ID: 18606527
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines for cancer.
Boyd D; Hung CF; Wu TC
IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
[TBL] [Abstract][Full Text] [Related]
12. Development of optimized cryptic peptides for immunotherapy.
Menez-Jamet J; Kosmatopoulos K
IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
[TBL] [Abstract][Full Text] [Related]
13. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.
Dietrich G; Spreng S; Favre D; Viret JF; Guzman CA
Curr Opin Mol Ther; 2003 Feb; 5(1):10-9. PubMed ID: 12669465
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the researches of DNA vaccines against tumors].
Lu Y; Tian L; Wei Y; Yang L; Zhao X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Aug; 17(4):288-90. PubMed ID: 10932018
[TBL] [Abstract][Full Text] [Related]
15. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
16. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
Yamano T; Kaneda Y; Hiramatsu SH; Huang S; Tran AN; Giuliano AE; Hoon DS
Cancer Gene Ther; 2007 May; 14(5):451-9. PubMed ID: 17318199
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
19. A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy.
Decker WK; Qiu J; Farhangfar F; Hester JH; Altieri DC; Lin AY
Cancer Lett; 2006 Jun; 237(1):45-55. PubMed ID: 16019131
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of MVA-based therapeutic cancer vaccines.
Acres B; Bonnefoy JY
Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
